Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2013 Nov 19

PMID 24240112

Citations 470

Authors

Kathryn P Pennington

Tom Walsh

Maria I Harrell

Ming K Lee

Christopher C Pennil

Mara H Rendi

Anne Thornton

Barbara M Norquist

Silvia Casadei

Alexander S Nord

Kathy J Agnew

Colin C Pritchard

Sheena Scroggins

Rochelle L Garcia

Mary-Claire King

Elizabeth M Swisher

Affiliations

Soon will be listed here.

Abstract

Purpose: Hallmarks of germline BRCA1/2-associated ovarian carcinomas include chemosensitivity and improved survival. The therapeutic impact of somatic BRCA1/2 mutations and mutations in other homologous recombination DNA repair genes is uncertain.

Experimental Design: Using targeted capture and massively parallel genomic sequencing, we assessed 390 ovarian carcinomas for germline and somatic loss-of-function mutations in 30 genes, including BRCA1, BRCA2, and 11 other genes in the homologous recombination pathway.

Results: Thirty-one percent of ovarian carcinomas had a deleterious germline (24%) and/or somatic (9%) mutation in one or more of the 13 homologous recombination genes: BRCA1, BRCA2, ATM, BARD1, BRIP1, CHEK1, CHEK2, FAM175A, MRE11A, NBN, PALB2, RAD51C, and RAD51D. Nonserous ovarian carcinomas had similar rates of homologous recombination mutations to serous carcinomas (28% vs. 31%, P = 0.6), including clear cell, endometrioid, and carcinosarcoma. The presence of germline and somatic homologous recombination mutations was highly predictive of primary platinum sensitivity (P = 0.0002) and improved overall survival (P = 0.0006), with a median overall survival of 66 months in germline homologous recombination mutation carriers, 59 months in cases with a somatic homologous recombination mutation, and 41 months for cases without a homologous recombination mutation.

Conclusions: Germline or somatic mutations in homologous recombination genes are present in almost one third of ovarian carcinomas, including both serous and nonserous histologies. Somatic BRCA1/2 mutations and mutations in other homologous recombination genes have a similar positive impact on overall survival and platinum responsiveness as germline BRCA1/2 mutations. The similar rate of homologous recombination mutations in nonserous carcinomas supports their inclusion in PARP inhibitor clinical trials.

Citing Articles

Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics.

Madeddu C, Lai E, Neri M, Sanna E, Gramignano G, Nemolato S Int J Mol Sci. 2025; 26(5).

PMID: 40076854 PMC: 11901047. DOI: 10.3390/ijms26052232.

Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review.

Wang Y, Allen I, Funingana G, Tischkowitz M, Joko-Fru Y BJC Rep. 2025; 3(1):14.

PMID: 40069561 PMC: 11897386. DOI: 10.1038/s44276-025-00122-9.

Intergroup-statement: statement of the german ovarian cancer commission, the North-Eastern German Society of gynecological Oncology (NOGGO), AGO Austria and AGO Swiss regarding the use of homologous repair deficiency (HRD) assays in advanced ovarian....

Chinczewski L, Harter P, Heukamp L, Mayr D, Grimm C, Heinzelmann-Schwarz V Arch Gynecol Obstet. 2025; .

PMID: 40069521 DOI: 10.1007/s00404-025-07991-y.

Significance of homologous recombinant deficiency as a biomarker for drug sensitivity in colorectal cancer.

Kato Y, Seishima R, Hattori K, Kato H, Ishida H, Shigeta K Br J Cancer. 2025; .

PMID: 39934338 DOI: 10.1038/s41416-025-02950-5.

Whole exome sequencing-based homologous recombination deficiency test for epithelial ovarian cancer.

Chiang Y, Huang H, Kuo K, Hwu W, Lin P J Ovarian Res. 2025; 18(1):19.

PMID: 39885596 PMC: 11780812. DOI: 10.1186/s13048-024-01565-3.

References

Norquist B, Wurz K, Pennil C, Garcia R, Gross J, Sakai W . Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol. 2011; 29(22):3008-15. PMC: 3157963. DOI: 10.1200/JCO.2010.34.2980. View

Mazoyer S, Dunning A, Serova O, Dearden J, Puget N, Healey C . A polymorphic stop codon in BRCA2. Nat Genet. 1996; 14(3):253-4. DOI: 10.1038/ng1196-253. View

Gupta A, Yang Q, Pandita R, Hunt C, Xiang T, Misri S . Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle. 2009; 8(14):2198-210. DOI: 10.4161/cc.8.14.8947. View

Fraser M, Zhao H, Luoto K, Lundin C, Coackley C, Chan N . PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res. 2011; 18(4):1015-27. PMC: 3378487. DOI: 10.1158/1078-0432.CCR-11-2189. View

Gelmon K, Tischkowitz M, MacKay H, Swenerton K, Robidoux A, Tonkin K . Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011; 12(9):852-61. DOI: 10.1016/S1470-2045(11)70214-5. View

Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood A . Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011; 306(14):1557-65. PMC: 4159096. DOI: 10.1001/jama.2011.1456. View

Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S . Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol. 2008; 26(1):20-5. DOI: 10.1200/JCO.2007.11.6905. View

Edwards S, Brough R, Lord C, Natrajan R, Vatcheva R, Levine D . Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008; 451(7182):1111-5. DOI: 10.1038/nature06548. View

Rafnar T, Gudbjartsson D, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A . Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet. 2011; 43(11):1104-7. DOI: 10.1038/ng.955. View

10.

Brown L, Kalloger S, Miller M, Shih I, McKinney S, Santos J . Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer. 2008; 47(6):481-9. DOI: 10.1002/gcc.20549. View

11.

Walsh T, Lee M, Casadei S, Thornton A, Stray S, Pennil C . Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A. 2010; 107(28):12629-33. PMC: 2906584. DOI: 10.1073/pnas.1007983107. View

12.

Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J . BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012; 30(21):2654-63. PMC: 3413277. DOI: 10.1200/JCO.2011.39.8545. View

13.

Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin S . EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell. 2003; 115(5):523-35. DOI: 10.1016/s0092-8674(03)00930-9. View

14.

Taniguchi T, Tischkowitz M, Ameziane N, Hodgson S, Mathew C, Joenje H . Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 2003; 9(5):568-74. DOI: 10.1038/nm852. View

15.

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

16.

McCabe N, Turner N, Lord C, Kluzek K, Bialkowska A, Swift S . Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006; 66(16):8109-15. DOI: 10.1158/0008-5472.CAN-06-0140. View

17.

Bolton K, Chenevix-Trench G, Goh C, Sadetzki S, Ramus S, Karlan B . Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA. 2012; 307(4):382-90. PMC: 3727895. DOI: 10.1001/jama.2012.20. View

18.

Walsh T, Casadei S, Lee M, Pennil C, Nord A, Thornton A . Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011; 108(44):18032-7. PMC: 3207658. DOI: 10.1073/pnas.1115052108. View

19.

Pritchard C, Salipante S, Koehler K, Smith C, Scroggins S, Wood B . Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn. 2013; 16(1):56-67. PMC: 3873496. DOI: 10.1016/j.jmoldx.2013.08.004. View

20.

Vencken P, Kriege M, Hoogwerf D, Beugelink S, van der Burg M, Hooning M . Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol. 2011; 22(6):1346-1352. DOI: 10.1093/annonc/mdq628. View